Loading stock data…
$6.89-0.37 (-5.10%)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
REGENXBIO Inc. in the Healthcare sector is trading at $6.89 with a market capitalization of $711M. Wall Street consensus targets $23.58 (12 analysts), implying a +242.3% move over the next 12 months. The stock is currently near its 52-week low of $5.46, remaining 28.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $108.02M↑ | $6.39M↓ | $30.34M↑ | $29.73M↑ | $21.36M |
| Gross Profit | $106.98M↑ | -$4.68M↓ | $24.41M↑ | $24.01M↑ | $16.15M |
| Operating Income | $29.26M↑ | -$83.36M↓ | -$57.64M↓ | -$52.41M↑ | -$63.28M |
| Net Income | $22.71M↑ | -$90.05M↓ | -$67.15M↓ | -$61.94M↑ | -$70.87M |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...